AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05539352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST) plus EUC
Description: All caregivers are assigned to this condition and receive EUC and PST. EUC is delivered along with the treatment to ensure the safety of all caregivers enrolled in the study. In addition to EUC, caregivers receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by caregivers and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress.
Study NCT05579522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat graft injection
Description: Fat graft injection in the interdental papilla.
Study NCT05579522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid injection
Description: Hyaluronic acid injection in the interdental papilla
Study NCT06276985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low intensity pulsed ultrasound and iPRF
Description: iPRF and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
Study NCT05090462 — intervention group
Intervention type: DEVICE
Intervention: PICO dressing
Description: Negative Pressure Wound Therapy device
Study NCT04895540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: All study subjects will undergo ECG recording.
Study NCT06692946 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatement as Usual
Description: Cognitive Behavioral Therapy (CBT) is a structured, short-term psychological treatment that focuses on identifying and changing negative thought patterns and behaviors. It aims to help individuals develop healthier ways of thinking and coping with challenges by addressing both cognitive (thought) and behavioral components.~Parent training is an educational intervention where parents learn strategies and techniques to effectively manage their child's behavior and support their development, often used to address challenges associated with conditions like autism or ADHD.
Study NCT04895540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: All study subjects will undergo transthoracic echocardiography
Study NCT04895540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: All ACM patients and SCD survivors will undergo cardiac MRI testing.
Study NCT04895540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory ECG recording
Description: All ACM patients and SCD survivors will undergo 24-hour ambulatory ECG recording
Study NCT06692218 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Leadless pacemaker
Description: Patients who will implant leadless pacemakers or already implanted leadless pacemakers since 1 Jan 2015 will be recruited. After the implantation, patients will be invited back for a noncontrast, ECG-gated CT heart. It will be timed at the end diastole and a 3D reconstruction will be performed.
Study NCT05079841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric breast pump
Description: Participants randomized to the intrapartum nipple stimulation will use electric breast pump or nipple stimulate by hand (if preferred) (intervention) to induce labor for at least 2 hours
Study NCT05079841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exogenous oxytocin intravenous infusion without nipple stimulation.
Description: Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor as current standard of care
Study NCT06317402 — intervention group
Intervention type: OTHER
Intervention: malnutrition questionary
Description: At the patient's bed, using a questionnaire, evaluators take anthropometric measurements (weight, height, muscle strength) and collect biological data (albumin, pre-albumin, CRP, if available in the medical record) to establish nutritional status according to HAS criteria for undernutrition 2019-2021 and 2003-2007.
Study NCT06399445 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional cold tonsillectomy and curettage adenoidectomy
Description: After entering the operating room, the children will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths, then we will set 4 % concentration of Sevoflurane. After loss of consciousness, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, Fentanyl 1 mcg/kg iv. and Propofol 2 mg/kg. During stage III of anesthetic depth, we will perform orotracheal intubation.
Study NCT06399445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional cold tonsillectomy and curettage adenoidectomy
Description: After entering the operating room, the children will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths, then we will set 4 % concentration of Sevoflurane. After loss of consciousness, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, Fentanyl 1 mcg/kg iv. and Propofol 2 mg/kg. During stage III of anesthetic depth, we will perform orotracheal intubation.
Study NCT06399445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: After entering the operating room, chlidren will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths. After loss of consciousness, we will turn off Sevoflurane, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, 1 mcg/kg Fentanyl, 2.5 mg/kg Propofol and 0.6 mg/kg Rocuronium bromide (esmeron). After 2 min, orotracheal intubation will be performed.
Study NCT05134571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laronidase
Description: Solution for injection; Intravenous
Study NCT04661202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal exercise training
Description: A supervised moderate-intensity exercise training session, which will include aerobic exercise with a stationary exercise bike, resistance exercise using dumbbell, theraband band, or gym ball for each major muscle groups and core muscles (including pelvic floor muscle (PFM) training with biofeedback), and stretching exercise, twice a week for 8 weeks. All exercises will be individualized based on participant's heart rate reserve and Rate of Perceived Exertion (RPE). An oximeter and a sphygmomanometer will be used to monitor the heart rate, oxygen saturation and blood pressure of the participants to ensure safety.~A home exercise program will include a walking exercise for 30 minutes per day and a PFM training with the aim of completing 1\~3 sets of 8\~12 submaximal contraction of PFM by holding 6\~10 seconds with 12\~20 seconds of rest between each contraction, and it will end with 3 maximal PFM contractions by holding 1\~3 seconds 3\~6 seconds of rest between each contraction.
Study NCT04995354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF loaded Hydrogel
Description: Patients will receive 25 Ug/day of EGF. This is the estimated daily dose that will be obtained when the patient applies the gel thrice daily. Patients will receive the treatment for one week
Study NCT04995354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: Non-medicated self-healing hydrogel to be applied three times a day for 1 week
Study NCT04895540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac EP study
Description: ACM patients and SCD survivors will undergo diagnostic cardiac Electrophysiology testing.
Study NCT06318546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex],,,
Description: patients will receive 0.5ml (10 µg) Dexmedetomidine as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
Study NCT06318546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: will be given 0.5 ml of one ampoule (2ml) of 100µg fentanyl (Fentanyl Hameln® 0.1mg/2ml - Sunny pharm) equivalent to 25 µg fentanyl as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
Study NCT04895540 — intervention group
Intervention type: GENETIC
Intervention: All study subjects will undergo sample collection for genetic testing.
Description: Blood samples and buccal swab will be collected from study subjects for genetic testing.
Study NCT06154850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality
Description: Oculus Quest 2 will be used with NatureTrek application for 10 minutes.
Study NCT05174754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-prescribed Exercise Programme
Description: A 20-week structured exercise programme derived and supervised by a Sports Medicine Physician following the FITT Principles
Study NCT05174754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Best Medical Therapy
Description: Best medical therapy with biologic agent or small-molecule therapy
Study NCT05174754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Medical Therapy
Description: Best medical therapy with biologic agent or small-molecule therapy
Study NCT05654363 — intervention group
Intervention type: PROCEDURE
Intervention: Administration of morphine by intrathecal route
Description: Lumbar puncture was performed before the induction of general anesthesia, in the operating room. Spinal anesthesia was performed in sitting position using a midline approach into the L3-L4 or L4-L5 interspaces with a 25ga pencil-point spinal needle administering 75-100 mcg morphine, with or without local anesthetic (levobupivacaine 0,5% 10-15 mg or bupivacaine 0,5% 10-15 mg or ropivacaine 0,5% 10-15 mg), depending on the anesthesiologist's preference. General anesthesia was then conducted according to clinical practice. All patients were transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery. Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
Study NCT05654363 — intervention group
Intervention type: PROCEDURE
Intervention: Administration of morphine by intravenous route
Description: General anesthesia was conducted according to clinical practice and a morphine bolus was administered before emergence from anesthesia according to clinical needs. All patients were then transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery and received Patient-Controlled Analgesia (PCA) with morphine 1mg/mL (CADD®-Solis 2110 Infusion System, Smiths Medical ASD, Inc., USA, 1 mL bolus on demand, no background infusion, 7 minute lockout, max 8 mg/h). Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
Study NCT04943887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSupport Health Weekly Group Sessions for PwMS
Description: A formal semi-structured program of psychoeducational support delivered in an online weekly small group format by health coaches (licensed therapists) who specialize in MS.
Study NCT06154850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-immersive virtual reality
Description: Patients will watch a video including scenes from NatureTrek application on a screen.
Study NCT04945369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical and biological measurements and questionnaires
Description: Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.~Assessment of body composition by BOP-POD and by impedancemetry. Assessment of pulse wave by popmetre. Assessment of physical activity by accelerometer and by questionnaire Questionnaires for analysis of eating behaviour
Study NCT06642870 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study
Description: The study will consist of focus groups and a large scale patient survey
Study NCT06248177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic capsules
Study NCT06248177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT06693505 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: caffeinated chewing gum
Description: two pieces of caffeinated chewing gum at an absolute dose of 200 mg (Military Energy Gum®, Ford Gum and Machine Go, Akron, NY, USA)
Study NCT06693505 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: two pieces of similar looking and tasting placebo gum that did not contain caffeine (xylitol, lime mint, green; Lotte, Saitama, Japan) (PLA trial)
Study NCT06693440 — intervention group
Intervention type: DRUG
Intervention: PD-1 Inhibitors
Description: Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
Study NCT06693180 — intervention group
Intervention type: OTHER
Intervention: HBOT
Description: Hyperbaric Oxygen Therapy
Study NCT04473937 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy at pre-determined dose and schedule
Study NCT06732037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy program
Description: The conventional physical therapy program will be received for 8 weeks by the two groups. It includes the application of moist heat using a hot pack for ten minutes, followed by continuous ultrasound therapy operated at a frequency of 1 MHz and an intensity of 1.5 W/cm² for five minutes. Transcutaneous Electrical Nerve Stimulation (TENS) will also be utilized, with its development and application based on the Gate Control Theory. TENS will be applied for twenty minutes, with electrodes positioned on either side of the neck at the level of pain, using a pulse rate ranging from 2 to 50 Hz.
Study NCT06732037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: The conventional physical therapy program will be received for 8 weeks by the two groups. It includes the application of moist heat using a hot pack for ten minutes, followed by continuous ultrasound therapy operated at a frequency of 1 MHz and an intensity of 1.5 W/cm² for five minutes. Transcutaneous Electrical Nerve Stimulation (TENS) will also be utilized, with its development and application based on the Gate Control Theory. TENS will be applied for twenty minutes, with electrodes positioned on either side of the neck at the level of pain, using a pulse rate ranging from 2 to 50 Hz.
Study NCT06732037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetic control training
Description: The Kinetic Control Retraining Program will be received for 8 weeks by the experimental group. It focuses on addressing uncontrolled movement (UCM) and muscle synergy retraining. UCM retraining starts with patient education on movement deficiencies, their symptoms, and adherence to training. Movement coordination is retrained in test positions, progressing to challenging ones using feedback from mirrors, walls, or hands. Corrections focus on lower cervical flexion, upper cervical extension, mid-cervical translation/extension, side-bending, and rotation, emphasizing controlled dissociation in supported and unsupported postures. Muscle synergy retraining targets global stabilizers (e.g., deep neck flexors and extensors) and mobilizers (e.g., sternocleidomastoid and suboccipital muscles) to enhance coordination, stability, and motor control.
Study NCT06746701 — intervention group
Intervention type: DRUG
Intervention: Peg-IFNα-2b combined with NA
Description: From baseline day 1, take NA orally once daily until the drug can be discontinued. Concurrently, combine with Peg-IFN α-2b 180μg, administered subcutaneously once a week for 48-96 weeks (if the surface antigen is not converted to negative at week 48, continue Peg-IFN α-2b treatment, but the course of treatment should not exceed 96 weeks). Discontinue Peg-IFN α-2b (while maintaining continuous oral administration of NA), and continue taking NA orally.
Study NCT06746701 — intervention group
Intervention type: DRUG
Intervention: Nucleotide Analogues
Description: Starting from the first day of enrollment, take NA orally once a day.
Study NCT05911009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BC 007 or matching placebo
Description: Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
Study NCT04725188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab coformuation
Description: Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
Study NCT04725188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
Study NCT04725188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
Study NCT04725188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline IV infusion Q3W up to approximately 2 years
Study NCT06325852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS programing
Description: The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.
Study NCT06402136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 83-0060
Description: Oral MPro inhibitor
Study NCT06402136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05911009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC 007 or matching placebo
Description: Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
Study NCT05411484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDOX® Hydrogel
Description: NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
Study NCT06343350 — intervention group
Intervention type: DEVICE
Intervention: OPTDR01 software application
Description: Retinal images will be sent to the OPTDR01 software application for mtmDR and vtDR detection
Study NCT05411484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 Ablative Fractional Laser
Description: CO2 Ablative Fractional Laser will be applied to healthy skin areas
Study NCT06644768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valemetostat tosylate
Description: Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
Study NCT06644768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
Study NCT06644768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
Study NCT06641401 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Flexor Hallucis Longus transfer for Acute Achilles tendon rupture
Description: All patients have already undergone the same operation for the same disease. All data are to be collected retrospectively
Study NCT06642844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin, 25 Mg/mL Intravenous Solution
Description: Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.
Study NCT06642844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin, 25 Mg/mL Intravenous Solution
Description: Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.
Study NCT04890314 — intervention group
Intervention type: OTHER
Intervention: Patient-reported questionnaire
Description: Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.
Study NCT06466434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prebiotic Food-Enriched Diet
Description: Given by PO
Study NCT05014126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain, Stress and Emotions
Description: 2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.